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Abstract
The consequences of early-life exposure to chemicals in the environment are emerging concerns. Chronic exposure
to naturally occurring inorganic arsenic has been known to cause various adverse health effects, including cancers,
in humans. On the other hand, animal studies by Dr. M. Waalkes’ group reported that arsenite exposure of pregnant
F0 females, only from gestational day 8 to 18, increased hepatic tumors in the F1 (arsenite-F1) males of C3H mice,
whose males tend to develop spontaneous hepatic tumors later in life. Since this mice model illuminated novel
unidentified consequences of arsenic exposure, we wished to further investigate the background mechanisms. In
the same experimental model, we identified a variety of factors that were affected by gestational arsenic exposure,
including epigenetic and genetic changes, as possible constituents of multiple steps of late-onset hepatic tumor
augmentation in arsenite-F1 males. Furthermore, our study discovered that the F2 males born to arsenite-F1 males
developed hepatic tumors at a significantly higher rate than the control F2 males. The results imply that the tumor
augmenting effect is inherited by arsenite-F2 males through the sperm of arsenite-F1. In this article, we summarized
our studies on the consequences of gestational arsenite exposure in F1 and F2 mice to discuss novel aspects of
biological effects of gestational arsenic exposure.
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Background
Arsenic is widely distributed in the environment. Occu-
pational exposure to various forms of arsenic com-
pounds, as well as chronic exposure to naturally
occurring background arsenic have been shown to cause
serious health problems, including skin lesions, cardio-
vascular diseases, neuronal disorders, and cancers, in
many areas in the world [1–6]. Arsenic is classified as a
Group 1 human carcinogen by the International Agency
for Research on Cancer (IARC). Numerous epidemio-
logical studies have identified associations between
chronic background inorganic arsenic exposure from
drinking water with the risk of cancers in multiple or-
gans, such as skin, lung, liver, bladder and kidney [1, 5].
The major arsenic species of concern in drinking water
are inorganic arsenite (trivalent) and arsenate (pentava-
lent). They affect biological processes and cause toxic ef-
fects through a number of modes of actions (MOA),
such as interacting with biological components in the
sulfhydryl group, producing oxidative stress, and altering
signal transduction [1, 3]. Epigenetic alterations such as
DNA methylation changes are also implicated in the
toxicity and carcinogenicity of arsenic [7–10]. Previous
studies in bacteria and mammalian cells in vitro re-
ported that arsenic has no or weak mutagenicity [1, 5].
On the other hand, since inorganic arsenite and arsenate
have been shown to be metabolized into organic arsenic
compounds having higher toxicity [11], we investigated
mutagenicity of inorganic arsenite in transgenic mice de-
veloped for detecting in vivo mutations, as described
later [12]. The results showed that arsenic exposure
prominently increases G:C to T:A transversion, which is
induced by oxidative stress. Thus, the involvement of
mutation in arsenic-induced cancer augmentation needs
to be reconsidered.
One of the emerging concerns about chemical exposure
is the consequences of early-life exposure. The adverse ef-
fects of gestational exposure to environmental factors can
lead to adult-onset diseases in the offspring and also in
subsequent generations [13–15]. Epidemiological studies
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reported an association between arsenic exposure in utero
as well as early childhood and an elevated risk of cancers
[4, 16, 17]. In a mouse model, Waalkes and colleagues re-
ported that gestational arsenite exposure of C3H mice,
whose males are predisposed to spontaneously develop
hepatic tumors in adulthood [18, 19], increases the hepatic
tumor incidence in their F1 male offspring [20, 21]. In the
same mouse model, we recently showed that gestational
arsenite exposure of C3H mice increases hepatic tumor
incidence not only in the males of F1 (arsenite-F1), but
also in the males of the offspring of arsenite-F1 (arsenite-
F2) [22, 23].
In this article, we will start with a brief overview of
animal models for studying carcinogenicity of arsenic in
the literature. Then, we summarize our studies on the
cancer augmenting effects of gestational arsenite expos-
ure in arsenite-F1 and arsenite-F2 males and discuss
their mechanisms, including epigenetics and mutation.
Animal models detecting arsenic carcinogenesis
Although animal studies to test arsenic carcinogenicity
by dosing inorganic arsenic have a long history from the
early 1900s, only a limited number of positive results
have been observed [1, 5]. Convincing results were ob-
tained in the 1990s when cancer promoting effects of
the main metabolite of inorganic arsenic, dimethylarsinic
acid (DMAV), given at 50-400 ppm in drinking water for
24 weeks, were investigated in rats pretreated with car-
cinogens [24]. Significant tumor promoting effects of
DMAV in drinking water was also reported by exposure
at 10-100 ppm for 32 weeks in another tumor model in
rats [25] and at 400 ppm for 25 weeks in a mice model
[26]. Following studies showed that administering only
DMAV in drinking water induced bladder tumors in
F344 rats at 50 and 200 ppm for 2 years [27], and aug-
mented lung tumors in A/J mice, which spontaneously
develop lung tumors, at 400 ppm for 50 weeks [28].
Arsenic concentrations in groundwater are generally
lower than 10 ppb. On the other hand, epidemiological
studies have reported higher levels of arsenic in drinking
water in some endemic areas where the association of
cancer risk and arsenic exposure by drinking water have
been detected. The average levels of arsenic in most of
those endemic areas were at most up to 1 ppm [5].
Thus, the results of animal studies suggested that ro-
dents are much more refractory to the carcinogenicity of
arsenic compared to humans. Given that animal models
are pivotal to elucidate the molecular mechanisms of
carcinogenicity, key factors which produce the difference
in susceptibility to arsenic carcinogenicity between
humans and rodents should be addressed to better
understand the mechanism and estimate its risk.
In 2003, more evidence on the tumor augmenting ef-
fects of arsenic was reported by Waalkes et al. [20]. They
demonstrated that administration of pregnant C3H mice
with drinking water containing 42.5 or 85 ppm sodium
arsenite only from day 8 to 18 of gestation significantly
augmented hepatic tumor incidence in the male off-
spring at 74 weeks of age. The study showed that fetuses
are highly susceptible to the tumor promoting effects of
arsenic compared to adult animals. Subsequently,
Waalkes and colleagues reported hypomethylation of the
promoter region of the estrogen receptor α (ERα) and
upregulation of ERα expression in the normal tissue of
tumor-bearing livers in the F1 males gestationally ex-
posed to arsenic, compared to the normal tissues of con-
trol mice [21]. Their study showed the possibility that
epigenetic regulation of ERα expression is implicated in
cancer augmentation in the exposed F1 males, since es-
trogen augments cellular growth. These results encour-
aged us to further investigate the mechanisms of the
tumor augmenting effects of arsenic, as described below.
Tumor augmenting effects in the liver of offspring
by maternal arsenic exposure
The accumulated body of previous studies reported that
arsenic acts as a tumor promoter through genetic, epi-
genetic, and metabolic alterations [25, 29, 30]. For ex-
ploring the mechanism of the augmenting effects of
gestational arsenic exposure on the complex tumorigenic
process, we investigated several factors, such as gene ex-
pression, mutation, and epigenetics in the C3H mice
model established by Waalkes et al. [20]. As described
below, we identified multiple factors that may be in-
volved in the hepatic tumor augmentation around
74 weeks of age in arsenite-F1 [22].
Late-onset gene expression changes, metabolic
change and oxidative stress
Global gene expression analysis of as yet non-tumor-
bearing livers at 74 weeks of age showed that two genes
(Creld2 and Slc25a30) are significantly upregulated and
two genes (Fabp4 and Ell3) were significantly downregu-
lated more than 2-fold in arsenite-F1 males compared to
the control males. Interestingly, time course analyses at
6, 49 and 74 weeks of age showed that the expression
changes of the 4 genes are late onset events, since their
expressions were not different in the control and
arsenite-F1 males at 6 weeks of age and the difference
between the two groups were firstly detected at 49 or
74 weeks of age (Fig. 1) [22].
The upregulation of Creld2 and downregulation of
Fabp4 suggested the involvement of lipid metabolism,
since Creld2 is an endoplasmic reticulum (ER) stress-
inducible gene [31] and lipogenesis is activated by ER
stress [32]. Fabp4 is one of the fatty acid–binding pro-
teins and is known to play a role in effluxing fatty acids
from adipocytes [33]. Lipid accumulation in the liver can
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lead to the promotion of tumorigenesis thorough oxida-
tive stress production [34]. The measurement of lipid con-
tents in the normal livers at 74 weeks of age showed a
16% increase of triglyceride in the arsenite-F1 males in
comparison with the control males. We also detected the
suppression of glycerol-3-phosphate acyltransferase-1
(Gpat-1), one of the target genes of sterol regulatory
element-binding protein 1 (Srebp1), the central transcrip-
tion factor which regulates the levels of cholesterol and
fatty acids [35]. We also detected upregulation of a repre-
sentative oxidative stress inducible gene, HO-1, in the nor-
mal livers of arsenite-F1 males compared to the control
males. These results suggest that gestational arsenic ex-
posure induces late-onset changes in gene expression
leading to changes in lipid metabolism and augmentation
of oxidative stress, which promote tumorigenesis [22].
Further biochemical studies are necessary to confirm the
levels of involved factors such as the enzymes.
Epigenetic changes
Epigenetic mechanisms, such as genomic DNA methyla-
tion, histone modification and small RNA manipulation,
play a role in the regulation of gene expression and
thereby adjust biological functions or cause disorders
[36–38].
DNA methylation occurring primarily at the 5-carbon
of the cytosine in CpG dinucleotides is produced by
DNA methyltransferases (DNMTs) and the level is regu-
lated by the balance between DNA methylation and ac-
tive and/or passive DNA demethylation [36, 38]. Global
DNA hypomethylation, i.e., a reduction in the total
amount of 5-methylcytosine (5meC), is a well-known
feature of cancer cells and leads to genomic instability,
whereas hypomethylation and hypermethylation of DNA
in promoter regions can facilitate and suppress gene ex-
pression, respectively. Post-translational modifications,
such as methylation and acetylation, of histone tails are
also involved in the regulation and maintenance of tran-
scription levels [36].
We investigated the involvement of epigenetic regula-
tion for the four genes (Creld2, Slc25a30, Fabp4 and
Ell3) whose expressions were different between the nor-
mal livers of the control and arsenite-F1 males [22]. As a
result, a clear association was observed between the
Fig. 1 Late-onset changes in gene expression in the non-tumor-bearing livers of F1 male mice gestationally exposed to arsenic. Expression of four
genes in the livers of control and gestationally arsenic-exposed mice was measured by real-time PCR at 6, 49, and 74 weeks of age and normalized to
the expression of cyclophilin B (CPB). The graphs show the ratio of expression in the arsenic group normalized to expression in the control group. The
data shown are the means ± S.E. (n = 11 for 6 w, n = 4 for 49 w, n = 8 for 74 w). * significant difference between the two groups at p < 0.05 (21)
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suppression of Fabp4 expression in arsenite-F1 males
and the significant increase in H3K9me2, which is the
hallmark of heterochromatin where transcription is sup-
pressed [36]. On the other hand, no change of DNA
methylation status in the promoter region was observed
in any genes.
To extend our knowledge on DNA methylation
changes by gestational arsenic exposure, we performed
genome wide DNA methylation analysis of normal hep-
atic tissues and hepatic tumor tissues in the control and
arsenite-F1 males by the methylated DNA immunopre-
cipitation (MeDIP)-CpG island microarray method [39].
We detected 16 DNA regions where methylation sta-
tuses were altered in the tumor tissues of arsenite-F1
males compared to the normal livers of the control F1
mice. Among them, we found that a gene body region of
Fosb, a member of the oncogene family, is hypermethy-
lated in the tumors of arsenite-F1 compared to the tu-
mors of the control males and the gene expression was
significantly increased corresponding to the DNA
methylation level. Several studies reported that higher
DNA methylation in the gene body region upregulates
gene expression [40–42]. Hence, the results of our study
suggest that gestational arsenic exposure affects gene ex-
pression by inducing DNA methylation in the gene body
region of Fosb. Although the role of Fosb in carcinogen-
esis is still unknown, gene expression change of Fosb
may play a part in tumor augmentation in arsenite-F1
males.
Ha-ras mutation
Several types of cancers in humans and mice frequently
contain mutation of the ras oncogene family (Ha-, Ki-,
and N-ras), which keeps the protein in the active form
and is thought to be an early event occurring in the initi-
ation stage and in driving tumorigenesis in various pro-
cesses [19, 43]. Previous studies reported that 9–60% of
the spontaneous hepatic tumors of C3H mice harbor a
Ha-ras mutation, primarily at codon 61 [17].
In our study, we detected three types of Ha-ras muta-
tions at codon 61 (C61A, A61T and A61G), with C61A
mutations predominating, in the hepatic tumor tissues
of the control and arsenite-F1 males around 74 weeks of
age. These mutations were shown to be somatically ac-
quired, since no mutations were detected in Ha-ras in
the normal tissues of the tumor-bearing livers. We fur-
ther found that gestational arsenite exposure tended to
increase the percentage of livers having tumors contain-
ing the Ha-ras mutation, and the percentage of livers
with C61A Ha-ras mutation was more than doubled in
arsenite-F1 males compared to the control males [22]. C
to A mutations, that is, G:C to T:A transversions, are in-
duced following the formation of 8-hydroxy-2-deoxygua-
nosine (8-OHdG), a representative product of oxidative
DNA damage [44]. As described above, our results sug-
gested that gestational arsenic exposure increases oxida-
tive stress in a late-onset manner through lipid
metabolism alteration. Thus, such an increase in oxida-
tive stress later in life may be involved in the increase in
hepatic Ha-ras mutation and tumor augmentation.
On the other hand, previous studies performed in bac-
teria and mammalian cells in vitro have reported that
inorganic arsenic shows no or weak mutagenicity. Inor-
ganic arsenic is metabolized in vivo into organic com-
pounds and their toxicities vary depending on the forms
[11]. However, the mutagenicity of arsenic has not been
fully assessed in animal models. Thus, using gpt delta
transgenic mice, in which gpt gene cassettes are inte-
grated on genomic DNA for detecting in vivo mutations
[45], we investigated in vivo mutagenicity of orally ex-
posed arsenite [12]. Male gpt delta mice were given
drinking water containing 85 ppm sodium arsenite for
3 weeks, and mutations in the hepatic genome were
assayed 2 weeks later. The assay showed approximately
a 1.5-fold significant increase in average mutation fre-
quency in the arsenite-treated mice in comparison with
the control mice. DNA sequencing of the gpt gene
showed a marked increase in G:C to T:A transversions
(46% of all mutations) in the arsenite-treated mice com-
pared to that in the control mice (5% of all mutations).
We also detected a significant increase in 8-OHdG in
the livers of arsenite-treated mice. These results demon-
strated that arsenite has mutagenicity, particularly
inducing an oxidative-stress-associated G:C to T:A
transversions in vivo [12]. Gestational arsenic exposure
may increase the chance of C to A mutation at codon 61
in Ha-ras in fetus hepatic cells via oxidative stress pro-
duction and the mutation may be involved in tumori-
genic transformation.
Retrotransposon Long interspersed nuclear
element-1 (Line-1) Activity
Line-1 retrotransposon is a major class of transposable
elements in humans and mice. Although most transpos-
able elements have been rendered inactive, Line-1 is cap-
able of autonomous retrotransposition, which exerts
mutagenic consequences by inserting into the genome
or by causing breaks in double-stranded DNA [46, 47].
Both ORF1 and ORF2 proteins, the products of open
reading frames 1 and 2, are required for its retrotranspo-
sition. In our study, we detected a significantly higher
expression of Line-1 ORF1 and ORF2 in the normal tis-
sues of tumor-bearing livers of arsenite-F1 males in
comparison with the control males at 74 weeks of age
(Fig. 2), and found that it is induced in a late-onset man-
ner since it was not detected at 6 or 49 weeks of age
[22]. These results suggest that gestational arsenic ex-
posure induces late-onset Line-1 activation in the liver
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and promotes genetic instability. Recent study in vitro
also reported that arsenic exposure to HepG2 cells
significantly increased Line-1 retrotransposition fre-
quency [48].
Taken together, our studies so far have proposed the
involvement of multiple factors in the tumor-
augmentation in the arsenite-F1 (Fig. 3).
Germ cell-transmitted effects in the F2 generation
Our recent study further demonstrated that only gesta-
tional arsenic exposure in the Waalkes’ model increases
tumor incidence even in the F2 generation (arsenite-F2)
[23]. The routes through which gestational arsenic ex-
posure affects F1 and F2 are totally different. The organs
of F1 offspring are directly exposed to arsenic during the
fetal period. Rapidly growing fetus organs are highly sus-
ceptible to chemicals since chemicals often disturb cellu-
lar differentiation and affect their plasticity [49].
Changes in hormone levels and metabolisms in the ex-
posed mothers can also affect fetal condition. On the
other hand, the F2 effect is transmitted through exposed
germ cells of F1 to the F2 generation. To elucidate the
transmission route of the F2 effect, we investigated
whether the tumor augmenting effects of gestational ar-
senic exposure originate with either male or female, or
both, of the F1 by reciprocal crossing between the con-
trol and arsenite-F1 males and females (Fig. 4) [23]. The
results showed that the F2 males born to arsenite-F1
males (AC and AA, Fig. 4) developed tumors at a signifi-
cantly higher rate than the F2 males born to the control
F1 males, irrespective of exposure of F1 females (CC and
CA, Fig. 4). These results showed that the sperm of F1
fathers is responsible for the transmission of tumor aug-
menting effects by gestational arsenite exposure into the
F2 males.
Epigenetic modifications of the genome (epigenome),
particularly DNA methylation modification, of germ
cells play a pivotal role in development. The DNA
methylation pattern is known to be dynamically repro-
grammed in pre-implantation embryos as well as in
Fig. 2 Increased Line-1 RNA expression in the livers of adult F1 male mice gestationally exposed to arsenic. Expression of ORF1 and ORF2 in normal
adult livers, normal tissue from tumor-bearing livers, and tumor tissue from tumor-bearing livers were measured by real-time PCR and normalized to
the expression of CPB. Results are reported as means ± S.E. (n = 6). * significant difference between the two groups at p < 0.05 (21)
Fig. 3 Possible actions of gestationally exposed arsenic in the hepatic tumorigenesis in F1 mice (22)
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primodial germ cells (PGCs), the precursor cells for both
spermatozoa and oocytes, emerging in a fetus [50]. The
epigenomes of these stages are thought to be vulnerable
to chemical exposure [13–15]. In our study, pregnant
mothers were exposed to arsenite in the gestational
period from GD8, around which time DNA methylation
of PGCs in the fetus undergoes tremendous reprogram-
ming. Arsenite may disturb the epigenome of PGCs in
the F1 males and augment hepatic tumors in the F2
males. At present, we do not know what changes cause
tumor augmentation in the F2 livers. To clarify this,
identification of tumor augmenting factors in the F2
livers and epigenetic alterations in the sperm, which
leads to tumor augmentation in the F2, by gestational ar-
senite exposure is required.
Furthermore, gestational exposures to a variety of en-
vironmental factors, including several chemicals, have
been reported to cause not only multigenerational (in F1
and F2), but also transgenerational effects that are inher-
ited by the F3 and following generations [14, 15]. In
addition to the tumor augmenting effects, we recently
demonstrated that arsenic exposure of pregnant mice
causes behavioral inflexibility and impaired cortical
structure in the F1 offspring [51]. A recent study by an-
other group reported that arsenic exposure of pregnant
mice leads to obesity and early onset of the vaginal
opening in the F1 females [52]. The consequences of
gestational exposure to arsenic also needs to be ad-
dressed multigenerationally and transgenerationally from
a long-term perspective.
Conclusion
Our studies showed that gestational arsenite exposure
induces late-onset gene expression changes in normal
livers and expansion of tumors having epigenetic and
genetic changes in the F1 males of C3H mice. Genomic
instability shown by up-regulation of Line-1 expression
and metabolic changes were implicated in hepatic tumor
augmentation. Furthermore, our study demonstrated
that tumor augmenting effects by gestational arsenite ex-
posure were transmitted to the F2 males through the F1
sperm. Animal studies are indispensable for elucidating
molecular mechanisms and predicting unclarified effects
of chemical exposure. Since rodents are demonstrated to
be highly refractory to arsenic compared to humans, ex-
perimental models using mice and rats adopt higher
doses of arsenic to develop symptoms similar to those
which are observed in humans. Considering the differ-
ences between rodents and humans, further studies on
the mechanisms are necessary to provide important data
to estimate multigenerational tumor-augmenting effects
of arsenic.
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